Association of a serotonin receptor 2A gene polymorphism with visual sustained attention in early-onset schizophrenia patients and their non-psychotic siblings

Aging and Disease

Volumn 3, Issue 4, 2012, Pages 291-300

  Vyas, Nora S ^a,b   Lee, Yohan ^a   Ahn, Kwangmi ^a   Ternouth, Andrew ^b   Stahl, Daniel R ^c   Al Chalabi, Ammar ^c   Powell, John F ^c   Puri, Basant K ^d  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Adolescence; Attention; Biological relatives; Gene polymorphism; Htr2a; Schizophrenia; T102c

Indexed keywords

EID: 84908250841     PISSN: None     EISSN: 21525250     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Meltzer HY and Nash J (1991). The effect of antipsychotic drugs on serotoninergic receptors. Pharmacol Rev, 43: 587-604.
2. Lieberman JA, Mailman RB, Duncan G, Sikich L, Chakos M, Nichols DE, Kraus JE (1998). Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol Psychiatry, 44: 1099-1117.
3. Harrison PJ (1999). Neurochemical alterations in schizophrenia affecting the putative receptor targets of atypical antipsychotics. Focus on dopamine (D1, D3, D4) and 5-HT2a receptors. Br J Psychiatry (Suppl.), 1: 12-22.
4. Hsieh CL, Bowcock AM, Farrer LA, Hebert JM, Huang KN, Cavalli-Sforza LL, Julius D and Francke U (1990). The serotonin receptor subtype 2 locus HTR2 is on human chromosome 13 near genes for esterase D and retinoblastoma-1 and on mouse chromosome 14. Soma Cell Mol Genet, 16: 567-574.
5. Patel NH, Vyas NS, Nijran, KS, Puri BK and Al-Nahhas A (2010). PET Imaging in Schizophrenia: A New Perspective. J Nucl Med, 51(4): 511-520.
6. Vyas NS, Patel NH, Nijran KS, Al-Nahhas A and Puri BK (2011). The Use of Positron Emission Tomography Imaging in Understanding Cognition, Genetics, and Psychopharmacology Interventions in Schizophrenia. Expert Rev Neurother, 11(1): 37-51.
7. Abdolmaleky HM, Faraone SV, Glatt SJ and Tsuang MT (2004). Meta analysis of association between the T102C polymorphism of the 5-HT2A receptor gene and schizophrenia. Schizophr Res, 67: 53-62.
8. Nocjar C, Roth BL and Pehek EA (2002). Localization of 5-HT(2A) receptors on dopamine cells in subnuclei of the midbrain A10 cell group. Neuroscience, 111: 163-176.
9. Rutschmann J, Cornblatt B and Erlenmeyer-Kimling L (1986). Sustained attention in children at risk for schizophrenia: findings with two visual continuous performance tests in a new sample. J Abnorm Child Psychol, 14: 365-385.
10. Golimbet VE, Alfimova MV and Mitiushina NG (2004). Polymorphism of the serotonin 2A receptor gene (5HTR2A) and personality traits. Mol Biol (Mosk), 38: 404-412.
11. Joober R, Benkelfat C, Brisebois K, Toulouse A, Turecki G, Lal S, Bloom D, Labelle A, Lalonde P, FortinD, Alda M, Palmour R, Rouleau GA (1999). T102C polymorphism in the 5-HT2A gene and schizophrenia: relation to phenotype and drug variability. J Psychiatry Neurosci, 24: 141-146.
12. Herken H, Erdal ME, Erdal N and Aynacioglu S (2003). T102C polymorphisms at the 5-HT2A receptor gene in Turkish schizophrenia patients: A possible association with prognosis. Neuropsychobiology, 4: 27-30.
13. Chen RY, Sham P, Chen EY, Li T, Cheung EF, Hui TC, Kwok CL, Lieh-Mak F, Zhao JH, Collier D and Murray R (2001). No association between T102C polymorphism of serotonin-2A receptor gene and clinical phenotypes of Chinese schizophrenic patients. Psychiatry Res, 105: 175-185.
14. Ertugrul A, Kennedy JL, Masellis M, Basile VS, Jayathilake K and Meltzer HY (2004). No association of the T102C polymorphism of the serotonin 2A receptor gene (HTR2A) with suicidality in schizophrenia. Schizophr Res, 69: 301-305.
15. Üçok A, Alpsan H, Cakir S and Saruhan-Direskeneli G (2007). Association of a serotonin receptor 2A gene polymorphism with cognitive functions in patients with schizophrenia. Am J Med Genet B Neuropsychiatr Genet, 144: 704-707.
16. Lane HY, Liu YC, Huang CL, Chang YL, Chang L, Chang L, Chang YC, Chang WH (2008). Prefrontal executive function and D(1), D(3), 5-HT(2A) and 5-HT(6) receptor gene variations in healthy adults. J Psychiatry Neurosci, 33: 47-53.
17. Alfimova MV, Monakhov MV, Abramova LI, Golubev SA and Golimbet VE (2010). Polymorphism of serotonin receptor genes (5-HTR2A) and dysbindin (DTNBP1) and individual components of short-term verbal memory processes in schizophenia. Neurosci Behav Physiol, 40: 934-940.
18. Inayama Y, Yoneda H, Sakai T, Ishida T, Nonomura Y, Kono Y, Takahata R, Koh J, Sakai J, Takai A, Inada Y and Asaba H (1996). Positive association between a DNA sequence variant in the serotonin 2A receptor gene and schizophrenia. Am J Med Genet, 67: 103-105.
19. Williams J, Spurlock G, McGuffin P, Nothen M and Owen MJ (1997). Meta-analysis of association between the 5-HT2A receptor T102C polymorphism and schizophrenia. European Multicentre Association Study of Schizophrenia (EMASS Group). Lancet, 26:1221.
20. Chugani HT (1998). A critical period of brain development: studies of cerebral glucose utilization with PET. Prev Med, 27: 184-188.
21. Vyas NS, Patel NH and Puri BK (2011). Neurobiology and phenotypic expression in early onset schizophrenia. Early Interv Psychiatry, 5: 3-14.
22. Cannon M, Caspi A, Moffitt TE, Harrington H, Taylor A, Murray RM and Poulton R (2002). Evidence for early-childhood, pan-developmental impairment specific to schizophreniform disorder: results from a longitudinal birth cohort. Arch Gen Psychiatry, 59: 449-456.
23. Vyas NS, Hadjulis M, Vourdas A, Byrne P and Frangou S (2007). The Maudsley early onset schizophrenia study. Predictors of psychosocial outcome at 4-year follow-up. Eur Child Adolesc Psychiatry, 16: 465-470.
24. Gogtay N, Vyas NS, Testa R, Wood SJ and Pantelis C (2011). Age of onset of schizophrenia: perspectives froom structural neuroimaging studies. Schizophr Bull, 37: 504-513.
25. Kenny JT, Friedman L, Findling RL, Swales TP, Strauss ME, Jesberger JA and Schulz SC (1997). Cognitive impairment in adolescents with schizophrenia. Am J Psychiatry, 154: 1613-1615.
26. Rapoport JL, Giedd JN, Gogtay N (2012). The neurodevelopmental model of schizophrenia: update 2012. Mol Psychiatry, 2012 Apr 10. doi: 10.1038/mp.2012.23. [Epub ahead of print].
27. Kumra S, Wiggs E, Bedwell J, Smith AK, Arling E, Albus K, Hamburger SD, McKenna K, Jacobsen LK, Rapoport JL, Asarnow RF (2000). Neuropsychological deficits in pediatric patients with childhood-onset schizophrenia and psychotic disorder not otherwise specified. Schizophr Res, 42: 135-144.
28. Brickman AM, Buchsbaum MS, Bloom R, Bokhoven P, Paul-Odouard R, Haznedar MM, Dahlman KL, Hazlett EA, Aronowitz J, Heath D and Shihabuddin L (2004). Neuropsychological functioning in first-break, never-medicated adolescents with psychosis. J Nerv Ment Dis, 192: 615-622.
29. Rhinewine JP, Lencz T, Thaden EP, Cervellione KL, Burdick KE, Henderson I, Bhaskar S, Keehlisen L, Kane J, Kohn N, Fisch GS, Bilder RM and Kumra S (2005). Neurocognitive profile in adolescents with early-onset schizophrenia: clinical correlates. Biol Psychiatry, 58: 705-712.
30. Karatekin C, White T and Bingham C (2008). Divided attention in youth- onset psychosis and attention deficit/hyperactivity disorder. J Abnorm Psychol, 117: 881-895.
31. Gur RE, Calkins ME, Gur RC, Horan WP, Nuechterlein KH, Seidman LJ and Stone WS (2007). The Consortium on the Genetics of Schizophrenia: neurocognitive endophenotypes. Schizophr Bull, 33: 49-68.
32. Greenwood TA, BraffDL, Light GA, Cadenhead KS, Calkins ME, Dobie DJ, Freedman R, Green MF, Gur RE, Gur RC, Mintz J, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI and Schork NJ (2007). Initial heritability analyses of endophenotypic measures for schizophrenia: the consortium on the genetics of schizophrenia. Arch Gen Psychiatry, 64: 1242-1250.
33. Horan WP, Greenwood TA, BraffDL, Gur RE and Green MF (2009). The use of neurocognitive endophenotypes in large-scale family genetic studies of schizophrenia. In: Ritsne MS. The Handbook of Neuropsychiatric Biomarkers, Endophenotypes and Genes, pp. 177-193.
34. Rutschmann J, Cornblatt BA and Erlenmeyer-Kimling L (1977). Sustained attention in children at risk for schizophrenia. Arch Gen Psychiatry, 34: 571-575.
35. Mirsky AF, Yardley SL, Jones BP, Walsh D and Kendler KS (1995). Analysis of the attention deficit in schizophrenia: A study of patients and their relatives in Ireland. J Psychiat Res, 29: 23-42.
36. Keefe RS, Silverman JM, Mohs RC, Siever LJ, Harvey PD, Friedman L, Lees Roitman SE, DuPre RL, Smith CJ, Schmeidler J and David KL (1997). Eye tracking, attention, and schizotypal symptoms in nonpsychotic relatives of patients with schizophrenia. Arch Gen Psychiatry, 54: 169-176.
37. Finkelstein JR, Cannon TD, Gur RE, Gur RC and Moberg P (1997). Attentional dysfunctions in neuroleptic-naïve and neuroleptic-withdrawn schizophrenic patients and their siblings. J Abnorm Psychol, 106: 203-212.
38. Chen WJ, Liu SK, Chang CJ, Lien YJ, Chang YH and Hwu HG (1998). Sustained attention deficit and schizotypal personality features in nonpsychotic relatives of schizophrenic patients. Am J Psychiatry, 155: 1214-1220.
39. Franke P, Maier W, Hardt J, Hain C and Cornblatt BA (1994). Attentional abilities and measures of schizotypy: their variation and covariation in schizophrenic patients, their siblings, and normal control subjects. Psychiatry Res, 54: 259-272.
40. Laurent A, Saoud M, Bougerol T, d'Amato T, Anchisi A, Biloa-Tang M, Dalery J and Rochet T (1999). Attentional deficits in patients with schizophrenia and in their non-psychotic first-degree relatives. Psychiatry Res, 89: 147-159.
41. Snitz BE, Macdonald AW III and Carter CS (2006). Cognitive deficits in unaffected first- degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes. Schizophr Bull, 32: 179-194.
42. Sitskoorn MM, Aleman A, Ebisch SJ, Appels MC and Kahn RS (2004). Cognitive deficits in relatives of patients with schizophrenia: a meta-analysis. Schizophr Res, 71: 285-295.
43. First M, Spitzer RL, Gibbon M and Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis 1 Disorders - Research Version, Patient Edition (SCID-I/P). Biometrics Research. New York, NY: New York State Psychiatric Institute, 2001.
44. First M, Spitzer RL, Gibbon M and Williams JBW. Structured Clinical Interview for DSM-IV -TR Axis 1 Disorders - Research Version, Non-patient Edition (SCID-I/NP). New York, NY: Biometrics Research, New York State Psychiatric Institute, 2002.
45. Bezchlibnyk-Butler KZ and Jeffries JJ (2000). Clinical Handbook of Psychotropic Drugs (10th rev. ed.). Toronto: Hogrefe and Huber.
46. Kay SR, Fiszbein A and Opler LA (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull, 13: 261-276.
47. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders. (4th ed.), American Psychiatric Association, Washington, DC.
48. Wechsler D (1991). Wechsler Adult Intelligence Scale-Revised. Ohio: The Psychological Corporation Cleveland.
49. Wechsler D (1992). Manual for the Wechsler Intelligence Scale for Children - Third Edition (WISC-III) UK Edition. Sidcup, Kent: The Psychological Corporation.
50. Nuechterlein KH, Parasuraman R and Jiang Q (1983).Visual sustained attention: image degradation produces rapid sensitivity decrements over time. Science, 220: 327-329.
51. Nuechterlein KH (1991). Vigilance in schizophrenia and related disorders. In: Steinhauer SR, Gruzelier JH, Zubin J, eds. Neuropsychology, Psychophysiology and Information Processing. Handbook of Schizophrenia; Volume 5. Amsterdam: Elsevier pp. 397-433.
52. Nuechterlein KH and Asarnow RF (1992). Manual and Computer Program for the UCLA Continuous Performance Test. UCLA, Los Angeles, Unpublished manual and program.
53. Freeman B, Smith N, Curtis C, Huckett L, Mill J and Craig IW (2003). DNA from buccal swabs recruited by mail: Evaluation of storage effects on long-term stability and suitability for multiplex polymerase chain reaction genotyping. Behavior Genetics, 33: 67-72.
54. Nelder J and Wedderburn R (1972). Generalized linear models. J R Stat Soc Ser A 135: 370-384.
55. Hardin J and Hilbe J (2003). Generalized Estimating Equations. London: Chapman and Hall.
56. Cohen, J. (1988). Statistical power analysis for the behavioral sciences. Second Edition. Hillsdale, NJ: Lawrence Erlbaum Associates, Publishers.
57. Boulougouris V and Tsaltas E (2008). Serotonergic and dopaminergic modulation of attentional processes. Prog Brain Res,172: 517-542.
58. Alfimova, MV, Golimbet VE and Mitiushina NG (2003). Polymorphism of the serotonin receptor (5-HTR2A) gene and verbal fluency in normalcy and schizophrenia. Mol Biol (Mosk), 37: 68-73.
59. Epstein JI, Keefe RSE, Roitman SL, Harvey PD and Mohs RC (1996). Impact of neuroleptic medications on continuous performance test measures in schizophrenia. Biol Psychiatry, 39: 902-905.
60. Cornblatt B, Obuchowski M, Schnur B and O'Brien JD (1997). Attention and clinical symptoms in schizophrenia. Psychiatr Quart, 68: 343-359.
61. Desimone R (1996) Neural mechanisms for visual memory and their role in attention. Proc Natl Acad Sci USA, 93: 13494-13499.
62. Gregoriou GG, Gotts SJ, Zhou H and Desimone R (2009). High-frequency, long-range coupling between prefrontal and visual cortex during attention. Science, 324: 1207-1210.
63. Cannon M, Jones P, Huttunen MO, Tanskanen A, Huttenen T, Rabe-Hesketh S and Murray RM (1999). School performance in Finnish children and later development of schizophrenia: a population-based longitudinal study. Arch Gen Psychiatry, 56: 457-463.
64. Vyas NS, Kumra S and Puri BK (2010). What insights can we gain from studying early-onset schizophrenia? The neurodevelopmental pathway and beyond. Expert Rev Neurother, 10: 1243-1247.
65. Vyas NS, Shamsi SA, Malhotra AK, Aitchison KJ and Kumari V (2012). Can genetics inform the management of cognitive deficits in schizophrenia? J Psychopharmacol, 26: 334-348.
66. Childs B and Scriver CR (1986). Age at onset and causes of disease. Perspect Biol